ArticleFrontiers in cell and developmental biology2026
Pharmacological inhibition of frizzled 4 delays cell cycle progression and limits oral squamous cell carcinoma growth.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Down-regulation of THBS2 inhibits the malignant progression of Burkitt lymphoma by blocking the PI3K/AKT/c-MYC pathway.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma is an aggressive malignancy driven by aberrant signaling pathways, with Wnt signaling acting as a central regulator of proliferation, tumor-microenvironment interactions, and oncogenic growth. Here, we focus on Frizzled-4, a Wnt receptor with context-dependent functions in epithelial cancers. We show that pharmacological inhibition of Frizzled-4 delays cell cycle progression, and reduces proliferative capacity. These effects are accompanied by suppressed metabolism of retinoic acid, suggesting that Frizzled-4 inhibition stabilizes intracellular retinoic acid levels, which ultimately contributes to the observed cell cycle slowdown. Blocking retinoic acid signaling reverses the cell cycle effects of Frizzled-4 inhibition, confirming that retinoic acid-dependent regulation operates downstream of Frizzled-4. By restraining uncontrolled proliferation and attenuating oncogenic signaling, Frizzled-4 emerges as a key molecular node in oral squamous cell carcinoma, highlighting its potential as a therapeutic target to counteract Wnt-driven tumor growth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.